1. Scrip
  2. >>Business
  3. >>Financing

IPO Update: What A Difference A (Pandemic) Year Makes

COVID-19 Paralyzed Market In Q1 2020 But Fortunes Reversed In 2021

 
• By Mandy Jackson

Just nine drug developers went public in the US during the first quarter of last year, but with the industry boosted by pandemic response, 32 biopharma companies launched IPOs in Q1 of this year.

IPO (Initial Public Offering) letters hanging from strings
32 biopharma companies went public in the US in Q1, raising $5.2bn and generating an 11% average return • Source: Shutterstock

The market for initial public offerings in the US was vastly different in the first quarter of 2020 than it was during the same period of 2021.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Biotech Leaders Fear FDA Disruption Is Causing Delays

 
• By Jessica Merrill

A letter to US Senate HELP Committee Chair Bill Cassiday sounds an alarm about irreparable damage to the FDA, signed by more than 200 biotech executives and investors.

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Q1 VC Financings Fall Short As Early Deals, Mega-Rounds Dip

 
• By Mandy Jackson

Evaluate data show that biopharma companies raising cash in the smallest and largest categories of venture capital financings struggled to meet bars set in prior quarters.